元祖股份(603886.SH):向全資子公司增資合計約2957.296萬元
格隆匯6月8日丨元祖股份(603886.SH)公吿,公司於2021年4月16日召開第三屆董事會第十一次會議審議通過了《關於向全資子公司增資的議案》。公司擬以自有資金向江蘇元祖、浙江元祖、上海元祖和元祖電商增資,上述四家公司合計增資約2957.296萬元,具體如下:
江蘇元祖增資803萬元,增資完成後註冊資本變更為2000萬元;浙江元祖增資194.776697萬元,增資完成後註冊資本變更為1000萬元;上海元祖增資59.5193萬元,增資完成後註冊資本變更為1000萬元;元祖電商增資1900萬元,增資完成後註冊資本變更為2000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.